CARLSBAD, Calif., Dec. 4 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (OTC Bulletin Board: IMNR), an immuno-pharmaceutical company
focused on developing products to treat autoimmune and infectious diseases,
announced that Dr. Joseph O'Neill, President and CEO, will present an
overview of the Company's immune-based therapies, currently in Phase II
clinical trials, at the Wall Street Analyst Forum Biotechnology &
Healthcare Conference (WSAF) in New York City.
The Company's presentation to the WSAF will take place on Thursday,
December 7, 2006, at 11:10 am (EST). A live webcast of this presentation
will be available at http://www.investorcalendar.com/CEPage.asp?ID=111522.
The online replay will be available for 30 days after the presentation.
Dr. O'Neill will discuss the Company's drug development pipeline, which
includes NeruoVax(TM), an investigational T-cell receptor (TCR) peptide
vaccine for the treatment of multiple sclerosis (MS) and IR103, for the
treatment of human immunodeficiency virus (HIV). He also intends to provide
an update on the 200-patient Phase IIb trial of NeuroVax(TM), which is
proceeding with Accelsiors CRO & Consultancy Services.
About The Immune Response Corporation
The Immune Response Corporation (OTC Bulletin Board: IMNR) is an
immuno-pharmaceutical company focused on developing products to treat
autoimmune and infectious diseases. The Company's lead immune-based
therapeutic product candidates are NeuroVax(TM) for the treatment of MS and
IR103 for the treatment of HIV infection. Both of these therapies are in
Phase II clinical development and are designed to stimulate disease
pathogen-specific immune responses aimed at slowing or halting the rate of
disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor
(TCR) peptide vaccine technology, has shown potential clinical value in the
treatment of relapsing forms of MS. NeuroVax(TM) has been shown to
stimulate strong, disease-specific cell-mediated immunity in nearly all
patients treated and appears to work by enhancing levels of FOXP3+ Treg
cells that are able to down regulate the activity of pathogenic T-cells
that cause MS. Increasing scientific findings have associated diminished
levels of FOXP3+ Treg cell responses with the pathogenesis and progression
of MS and other autoimmune diseases such as rheumatoid arthritis (RA),
psoriasis and Crohn's disease. In addition to MS, the Company has open
Investigational New Drug Applications (IND) with the FDA for clinical
evaluation of TCR peptide-based immune-based therapies for RA and
psoriasis.
IR103 is based on the Company's patented, whole-inactivated virus
technology, co-invented by Dr. Jonas Salk and indicated to be safe and
immunogenic in extensive clinical studies of REMUNE(R), the Company's first
generation HIV product candidate. IR103 is a more potent formulation that
combines its whole-inactivated antigen with a synthetic Toll-like receptor
(TLR-9) agonist to create enhanced HIV-specific immune responses. The
Company is currently testing IR103 in two Phase II clinical studies as a
first-line treatment for drug-naive HIV-infected individuals not yet
eligible for antiretroviral therapy according to current medical
guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune
Response Corporation and are not approved by any regulatory agencies in any
country at this time. Please visit The Immune Response Corporation at
http://www.imnr.com.
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could,
will, might, plan, projection, forecast, expect, guidance, potential and
developing. Actual results could vary materially from those expected due to
a variety of risk factors, including whether the Company will continue as a
going concern and successfully raise proceeds from financing activities
sufficient to fund operations and additional clinical trials of
NeuroVax(TM) or IR103, the uncertainty of successful completion of any such
clinical trials, the fact that the Company has not succeeded in
commercializing any drug, the risk that NeuroVax(TM) or IR103 might not
prove to be effective as either a therapeutic or preventive vaccine,
whether future trials will be conducted and whether the results of such
trials will coincide with the results of NeuroVax(TM) or IR103 in
preclinical trials and/or earlier clinical trials. A more extensive set of
risks is set forth in The Immune Response Corporation's SEC filings
including, but not limited to, its Annual Report on Form 10-K for the year
ended December 31, 2005, and its subsequent Quarterly Reports filed on Form
10-Q. The Company undertakes no obligation to update the results of these
forward-looking statements to reflect events or circumstances after today
or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
INVESTOR CONTACT: COMPANY CONTACT:
Gene Marbach Michael K. Green, COO and CFO
Makovsky & Company The Immune Response Corporation
(212) 508-9645 (760) 431-7080
gmarbach@makovsky.com info@imnr.com
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.investorcalendar.com/CEPage.asp?ID=111522
http://www.imnr.com
CONTACT:
Investors, Gene Marbach of Makovsky &
Company, +1-212-508-9645, gmarbach@makovsky.com, for The Immune
Response Corporation; or Michael K. Green, COO and CFO of The
Immune Response Corporation, +1-760-431-7080, info@imnr.com
|
